Johnson Pharmacare Ltd files audited results for FY 2025-26 and Q4 2026

What Johnson Pharmacare Ltd announced

Johnson Pharmacare Ltd (BSE: 532154) filed its audited financial results for the quarter and the full financial year ended 31 March 2026. The submission was made to the Bombay Stock Exchange on 19 June 2026 at 13:11 UTC. The filing complies with the regulatory requirement for listed companies to disclose audited results within the stipulated timeline.

Details of the filing

The announcement, titled "Submission of Audited Financial Results of Johnson Pharmacare Ltd for the quarter and year ended on March 31st 2026," does not provide any quantitative data such as revenue, profit before tax, or earnings per share. It merely confirms that the audited statements have been submitted and are available for shareholders and regulators via the BSE portal.

Key facts at a glance

Why this matters for investors

The filing confirms that Johnson Pharmacare Ltd has complied with statutory disclosure norms by submitting its audited results for the most recent reporting period. While the announcement itself does not reveal the underlying financial performance, the availability of the audited statements allows investors to review the company's profitability, cash flows, and balance‑sheet health for the year. The timing of the filing—within the regulatory window—helps maintain transparency and may affect future corporate actions that depend on disclosed earnings, such as dividend declarations or capital allocation decisions.

Conclusion

Johnson Pharmacare Ltd has officially lodged its audited FY 2025‑26 and Q4 2026 financial statements with BSE on 19 June 2026. The brief announcement does not disclose the actual numbers; interested parties should refer to the PDF filing for detailed financial metrics. No further regulatory approvals are indicated as pending in this submission.